Aug. 19 /PRNewswire/ -- Charlesson LLC, a specialty biopharmaceutical company, has been ranked by Inc. magazine as No. 264 on the 28th annual Inc. 500, an exclusive ranking of the fastest-growing private companies nationwide. Charlesson was also identified as the 23rd fastest-growing private company in the health category.
Charlesson was recognized as a result of its high growth rate, which totaled 858 percent over the past three years. Founded in 2003, Charlesson's primary focus is the development of treatments for eye diseases, including diabetic retinopathy, age-related macular degeneration and glaucoma. The company's expertise in ophthalmic drug development and delivery has also enabled it to establish a profitable contract research organization, which provides specialty preclinical ophthalmic services to major pharmaceutical companies.
"We are honored to be included in the prestigious group of companies in the Inc. 500 listing," said Mike Moradi, Chief Executive Officer of Charlesson. "Our ranking is a testament to the uniqueness of our ideas and the quality of our employees at Charlesson."
Despite the ongoing recession, the 2009 Inc. 500 offers a glimpse of the future of the U.S. economy. In the health sector, which saw aggregate revenue of $1.1 billion and a 917 percent median growth rate, businesses are moving forward on cancer and stem-cell research, clinical trials, and medication management.
The 2009 Inc. 500 measures revenue growth from 2005 through 2008. To qualify, companies must have been founded and generating revenue by the first week of 2005, and therefore able to show four full calendar years of sales. Additionally, they had to be U.S.-based, privately held, for profit, and independent -- not subsidiaries or divisions of other companies -- as of December 31, 2008. (Since then, a number of companies on the list have gone public or been acquired). The minimum revenue required for 2005 is $200,000; the minimum for 2008 is $2 million.
About Inc. Magazine
Founded in 1979 and acquired in 2005 by Mansueto Ventures LLC, Inc. (www.inc.com) is the only major business magazine dedicated exclusively to owners and managers of growing private companies that delivers real solutions for today's innovative company builders. With a total paid circulation of 712,961, Inc. provides hands-on tools and market-tested strategies for managing people, finances, sales, marketing, and technology. Visit us online at Inc.com.
Charlesson LLC is actively engaged in the development of therapeutics for treating numerous ocular diseases. The company's product pipeline includes pharmaceutical treatments for diabetic macular edema, age-related macular degeneration, retinitis pigmentosa, stargardt disease and diabetic retinopathy. Charlesson is also developing novel strategies to enhance drug delivery to the eye. In addition, the company offers outsourced preclinical services for the pharmaceutical industry, to screen drug candidates in Charlesson's novel in vivo and in vitro models for ocular disease. The company was founded in 2003 and is self-funded.
For further information: see http://www.charlessonllc.com.